Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine the safety and efficacy of GSK933776 in the treatment of geographic atrophy secondary to age-related macular degeneration.


Clinical Trial Description

This is a Phase 2a proof of concept study designed to evaluate the safety and efficacy of GSK933776 for the treatment of geographic atrophy secondary to age-related macular degeneration. This is a placebo-controlled parallel-group study that is double masked. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01342926
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 2
Start date June 2011
Completion date April 2016

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03845582 - Phase 3 Study of ALK-001 in Geographic Atrophy Phase 3
Completed NCT02033668 - Pharmacokinetic (PK) Study of GSK933776 in Healthy Volunteers Phase 1